A blood test can help predict the risk of relapse in operable lung cancer
allautoe 0 GECP news
A study by the Spanish Lung Cancer Group (GECP), published in Clinical Cancer Research, demonstrates that a blood test capable of detecting Minimal Residual Disease (MRD) after surgery significantly improves the prediction of relapse risk.
The results reveal that, although only 9.6% of patients were MRD-positive, all developed a relapse—in many cases, up to 8 months before it was detectable by imaging tests.
Mariano Provencio, president of GECP, emphasizes that, “if these results are confirmed in larger studies, we will be able to better personalize post-surgical treatments, avoiding unnecessary therapies and focusing efforts on those who really need them.”
Posted in notícias